WO2026041127 - NLRP3 INHIBITORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/041127
Publication Date
26.02.2026
International Application No.
PCT/CN2025/116446
International Filing Date
22.08.2025
Title **
[English]
NLRP3 INHIBITORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[French]
INHIBITEURS DE NLRP3, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION
[Chinese]
NLRP3抑制剂及其制备方法和用途
Applicants **
ZHEJIANG PANTHEON INNOVATION PHARMACEUTICAL CO., LTD
Inventors
ZHANG, Fengmin
ZHANG, Sicheng
ZHOU, Guoliang
Priority Data
202411163102.5
23.08.2024
CN
202510411701.2
02.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1720 | |
| EPO | Filing, Examination, Granting | 11640 | |
| Japan | Filing, Examination, Granting | 2061 | |
| South Korea | Filing, Examination, Granting | 1966 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,127
Contact Us
Abstract[English]
The present invention relates to the technical field of medicines, and specifically relates to a compound represented by formula (IV), or a stereoisomer, tautomer, deuterated derivative, or pharmaceutically acceptable salt thereof, and a preparation method therefor and a pharmaceutical use thereof. The compound can be used for treating or preventing NLRP3-related diseases or conditions.[French]
La présente invention se rapporte au domaine technique des médicaments, et concerne plus particulièrement un composé représenté par la formule (IV), ou un stéréoisomère, un tautomère, un dérivé deutéré, ou un sel pharmaceutiquement acceptable de celui-ci, ainsi que son procédé de préparation et son utilisation pharmaceutique. Le composé peut être utilisé pour traiter ou prévenir des maladies ou affections liées à NLRP3.[Chinese]
本发明属于医药技术领域，具体涉及式(IV)所示的化合物，或其立体异构体、互变异构体、氘代物或药用盐，及其制备方法和在医药上的应用，所述化合物可以用于治疗或预防与NLRP3相关的疾病或病症。